Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Held

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Acta Crystallographica. Section E, Structure Reports Online|July 15, 2011
Neodymium(III) molybdenum(VI) borate, NdBO(2)MoO(4)Peter Held, Benjamin van der Wolf, Ladislav Bohatý, et al.
American Heart Journal|January 25, 2008
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trialMarco J D Tangelder, Lars Frison, Douglas Weaver, et al.
European Heart Journal|October 3, 2003
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failureRobert S McKelvie, Jean-Lucien Rouleau, Michel White, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialJohn J V McMurray, Jan Ostergren, Karl Swedberg, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialSalim Yusuf, Marc A Pfeffer, Karl Swedberg, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialChristopher B Granger, John J V McMurray, Salim Yusuf, et al.
American Heart Journal|March 25, 2014
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trialMarc P Bonaca, Deepak L Bhatt, Eugene Braunwald, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|August 28, 2015
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and designS Claiborne Johnston, Pierre Amarenco, Gregory W Albers, et al.
Clinical Trials (London, England)|February 20, 2008
Do we need to adjudicate major clinical events?Christopher B Granger, Victor Vogel, Steve R Cummings, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Acta Crystallographica. Section E, Structure Reports Online|July 15, 2011
Neodymium(III) molybdenum(VI) borate, NdBO(2)MoO(4)Peter Held, Benjamin van der Wolf, Ladislav Bohatý, et al.
American Heart Journal|January 25, 2008
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trialMarco J D Tangelder, Lars Frison, Douglas Weaver, et al.
European Heart Journal|October 3, 2003
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failureRobert S McKelvie, Jean-Lucien Rouleau, Michel White, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialJohn J V McMurray, Jan Ostergren, Karl Swedberg, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialSalim Yusuf, Marc A Pfeffer, Karl Swedberg, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialChristopher B Granger, John J V McMurray, Salim Yusuf, et al.
American Heart Journal|March 25, 2014
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trialMarc P Bonaca, Deepak L Bhatt, Eugene Braunwald, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|August 28, 2015
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and designS Claiborne Johnston, Pierre Amarenco, Gregory W Albers, et al.
Clinical Trials (London, England)|February 20, 2008
Do we need to adjudicate major clinical events?Christopher B Granger, Victor Vogel, Steve R Cummings, et al.
Pageof 5